KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Capital Employed: 2013-2025

Historic Return on Capital Employed for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to -0.22%.

  • Travere Therapeutics' Return on Capital Employed rose 84.00% to -0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.22%, marking a year-over-year increase of 84.00%. This contributed to the annual value of -0.66% for FY2024, which is 4.00% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Return on Capital Employed is -0.22%, which was up 53.42% from -0.48% recorded in Q2 2025.
  • Travere Therapeutics' 5-year Return on Capital Employed high stood at -0.22% for Q3 2025, and its period low was -1.06% during Q3 2024.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.59% (2023), whereas its average is -0.66%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by 47bps in 2024, then surged by 84bps in 2025.
  • Over the past 5 years, Travere Therapeutics' Return on Capital Employed (Quarterly) stood at -0.31% in 2021, then declined by 27bps to -0.57% in 2022, then decreased by 4bps to -0.61% in 2023, then slumped by 32bps to -0.93% in 2024, then skyrocketed by 84bps to -0.22% in 2025.
  • Its Return on Capital Employed stands at -0.22% for Q3 2025, versus -0.48% for Q2 2025 and -0.58% for Q1 2025.